Prediction: 2026 Will Be the Year of Eli Lilly

04:10am, Monday, 19'th Jan 2026
Eli Lilly is tackling a high-growth market: weight loss. The company's weight loss portfolio brought in $10 billion in the recent quarter.
Representative Julie Johnson (D-Texas) recently sold shares of Eli Lilly and Company (NYSE: LLY). In a filing disclosed on January 15th, the Representative disclosed that they had sold between $1,001
Senator Markwayne Mullin (R-Oklahoma) recently bought shares of Eli Lilly and Company (NYSE: LLY). In a filing disclosed on January 16th, the Senator disclosed that they had bought between $15,001 and
Fiduciary Family Office LLC boosted its stake in Eli Lilly and Company (NYSE: LLY) by 28.3% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commi
About Yahoo Finance: Yahoo Finance provides free stock ticker data, up-to-date news, portfolio management resources, comprehensive market data, advanced tools, and more information to help you manage
Eli Lilly is getting its hands on a promising pipeline candidate thanks to an acquisition. The stock may not gain much more this year than it already has because of this news.
The article provides a methodology for selecting high-growth dividend-paying stocks, focusing on dividend growth and sustainability rather than high current yield. We use our proprietary models to rat
Eli Lilly is partnering with Nvidia to build an AI research lab. The drugmaker has made several AI moves in recent years.
Explore the exciting world of Eli Lilly (LLY +0.53%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trend
Guru Stock PicksRichard Pzena has made the following transactions:Add in MBUU by 2.48%Stock News Stocks end flat as chips rally: Taiwan Semiconductor (TSM) and
Novo Nordisk (NVO) shares climbed about 4% on Friday, touching levels last seen in October, after early U.S. prescription data for its Wegovy weight-loss pill p
Eli Lilly leads the weight loss market ahead of Novo Nordisk. Eli Lilly also has a more diversified lineup of products than its peer.
Eli Lilly stock declines after the FDA reportedly delays a decision on its obesity pill orforglipron, pushing the timeline to April and giving NVO more time.
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Buy The Dip In LLY Stock?

09:50am, Friday, 16'th Jan 2026
Eli Lilly's recent decline of 3.76% following the FDA's delay regarding its oral weight-loss pill Orforglipron signifies a strategic buying chance rather than a matter of concern. Although the stock i
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE